photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer Medical Treatment

FOLFIRINOX Induces a Full Pathological Response Leading to Resectability in Pancreatic Cancer

The four-drug FOLFIRINOX regimen represents a standard-of-care initial treatment for pancreatic cancer (ductal adenocarcinoma of the pancreas) despite substantive side-effects. Along with the gemcitabine plus Abraxane combination therapy it appears to offer survival advantage in pancreatic cancer over gemcitabine given alone. And increasingly, FOLFIRINOX is offered as therapy for locally advanced and “borderline resectable” pancreatic […]

Tumor Scrubbing Bubbles in Pancreatic Cancer

We all agree that pancreatic cancer (ductal adenocarcinoma of the pancreas) patients need more effective treatments. Towards that goal, much research time, money and effort go into the new treatment pipeline where only a tiny fraction will emerge with approval for pancreatic cancer, up to a decade later. I’ve advocated that today’s patients need something […]

Modified Irinotecan for Multi-drug Treatment of Pancreatic Cancer – an Update

More than a year ago (10/22/15), the U.S. Food and Drug Administration approved a modified form of the FOLFIRINOX regimen as a second line treatment for patients with metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas) whose gemcitabine-based therapy had failed.  We reported this development Here. The modified FDA-approved regimen was different from the “standard” […]

Page 3 of 1112345...10...Last »
Facebook
Facebook